Insider Selling: Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Sells 8,000 Shares of Stock

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $44.08, for a total value of $352,640.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of TRHC traded up $0.66 during mid-day trading on Monday, reaching $44.52. The company’s stock had a trading volume of 472,692 shares, compared to its average volume of 384,918. Tabula Rasa HealthCare Inc has a 12-month low of $40.86 and a 12-month high of $91.16. The company has a market cap of $964.41 million, a P/E ratio of 130.94 and a beta of 1.68. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.73 and a current ratio of 1.80.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). The firm had revenue of $60.96 million during the quarter, compared to analysts’ expectations of $59.24 million. Tabula Rasa HealthCare had a positive return on equity of 4.22% and a negative net margin of 18.15%. As a group, analysts predict that Tabula Rasa HealthCare Inc will post -0.55 earnings per share for the current fiscal year.

TRHC has been the topic of several recent research reports. Cantor Fitzgerald restated a “buy” rating and set a $99.00 price target on shares of Tabula Rasa HealthCare in a report on Thursday, February 28th. Zacks Investment Research downgraded Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 8th. BidaskClub upgraded Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Tuesday, May 7th. ValuEngine downgraded Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Finally, Guggenheim initiated coverage on Tabula Rasa HealthCare in a report on Wednesday, April 17th. They set a “neutral” rating and a $58.00 price target on the stock. Five analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Tabula Rasa HealthCare presently has an average rating of “Buy” and an average target price of $82.12.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Citigroup Inc. grew its position in shares of Tabula Rasa HealthCare by 2,337.1% in the first quarter. Citigroup Inc. now owns 309,588 shares of the company’s stock valued at $17,467,000 after purchasing an additional 296,885 shares during the period. Macquarie Group Ltd. grew its position in shares of Tabula Rasa HealthCare by 1,418.9% in the fourth quarter. Macquarie Group Ltd. now owns 316,040 shares of the company’s stock valued at $20,151,000 after purchasing an additional 295,233 shares during the period. Wellington Management Group LLP purchased a new stake in shares of Tabula Rasa HealthCare in the first quarter valued at $12,233,000. Rice Hall James & Associates LLC purchased a new stake in shares of Tabula Rasa HealthCare in the first quarter valued at $9,923,000. Finally, Jennison Associates LLC grew its position in shares of Tabula Rasa HealthCare by 17.2% in the first quarter. Jennison Associates LLC now owns 885,611 shares of the company’s stock valued at $49,966,000 after purchasing an additional 130,137 shares during the period. 86.66% of the stock is owned by institutional investors and hedge funds.

WARNING: “Insider Selling: Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Sells 8,000 Shares of Stock” was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.wkrb13.com/2019/06/11/insider-selling-tabula-rasa-healthcare-inc-nasdaqtrhc-ceo-sells-8000-shares-of-stock.html.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Featured Article: Moving Average Convergence Divergence (MACD)

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.